We report two examples of oncogene-driven NSCLC patients infected by SARS-CoV-2 who maintained targeted therapy with ALK/ROS1 TKIs and recovered without special antiviral therapies (Leonetti et al., 2020). The gene discussed is ALK; the disease is non-small cell lung carcinoma.